Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: An immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status

Pathology International

Volumn 46, Issue 12, 1996, Pages 953-961

  Moriki, Toshiaki ^a   Takahashi, Tamotsu ^a   Kataoka, Hiromi ^a   Hiroi, Makoto ^a   Yamane, Toshiko ^b   Hara, Hiroshi ^c  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b The Public Health Institute of Kochi Prefecture   (Japan)

^c Aichi Institute of Technology   (Japan)

Author keywords

Breast carcinoma; Bromodeoxyuridine; c erbB 2; Estrogen receptor; Histological grade; Immunohistochemistry; MIB 1; p53; Proliferating cell nuclear antigen

Indexed keywords

BROXURIDINE; CYCLINE; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY KI 67; PROTEIN P53; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER SIZE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030462119     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1996.tb03574.x     Document Type: Article

References (40)

1. Biesterfeld S, Noll I, Noll E, Wohltmann D, Boecking A. Mitotic frequency as a prognostic factor in breast cancer. Hum. Pathol. 1995; 26: 47-52.
2. Kallioniemi OP, Blanco G, Alavaikko M et al. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction: A proposed classification of DNA histogram in breast cancer. Cancer 1988; 62: 2183-2190.
3. Meyer JS, Province M. Proliferative index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res. Treat 1988; 12: 191-204.
4. Rudas M, Gnant MFX, Mittlboeck M et al. Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation with prognosis. Breast Cancer Res. Treat. 1994; 32: 165-175.
5. Meyer JS, Koehm SL, Hughes JM et al. Bromodeoxyuridine labeling for S-phase measurement in breast carcinoma. Cancer 1993; 71: 3531-3540.
6. Weidner N, Moore DH, Ljung BM et al. Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade. Am. J. Surg. Pathol. 1993; 17: 987-994.
7. Sasaki K, Matsumura K, Murakami T, Tsuji T. Measurement of bromodeoxyuridine labeling index, Ki-67 score and Ag-NOR count in breast carcinomas. Oncology 1992; 49: 147-153.
8. Gaglia P, Bernardi A, Venesio T et al. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: Its prognostic value on short-term recurrences. Eur. J. Cancer 1993; 29: 1509-1513.
9. Moriki T, Takahashi T, Hiroi M, Yamane T, Hara H. Histological grade in invasive ductal carcinoma of breast correlates with the proliferative activity evaluated by BrdU: An immunohistochemical study including correlations with p53, c-erbB-2 and estrogen receptor status. Pathol. Int. 1996; 46: 417-425.
10. Barnard JN, Hall PA, Lemoine NR, Kadar N. Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to clinical and pathological variables. J. Pathol. 1987; 152: 287-295.
11. Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP. Evaluation of cell proliferation and DNA content in breast carcinoma: Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis and mitotic count. Cancer 1990; 65: 1180-1184.
12. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kylloenen L, von Smitten K. Prognostic value of Ki-67 immunolabeling in primary operable breast cancer. Br. J. Cancer 1993; 68: 579-583.
13. Leonardi E, Girlando S, Serio G et al. PCNA and Ki-67 expression in breast carcinoma: Correlations with clinical and biological variables. J. Clin. Pathol. 1992; 45: 416-419.
14. Siitonen SM, Isola JJ, Rantala IS, Helin HJ. Intratumor variation in cell proliferation in breast carcinoma as determined by antiproliferating cell nuclear antigen monoclonal antibody and automated image analysis. Am. J. Clin. Pathol. 1993; 99: 226-231.
15. Tahan SR, Neuberg DS, Dieffenbach A, Yacoub L. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 1993; 71: 3552-3559.
16. Schmitt FC, Pereira EM, Andrad LM, Torresan M, Lucca L. The proliferating cell nuclear antigen index in breast carcinomas does not correlate with mitotic index and estrogen receptor immunoreactivity. Pathol. Res. Pract. 1994; 190: 786-791.
17. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br. J. Cancer 1957; 11: 359-377.
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I: The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
19. Cattoretti G, Becker MHG, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol. 1992; 168: 357-363.
20. Weidner N, Moore DH, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel 'paraffin'-reactive MIB-1 antibody. Hum. Pathol. 1994; 25: 337-342.
21. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma: Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am. J. Clin. Pathol. 1995; 104: 42-49.
22. Remmele W, Muehlfait V, Keul HG. Estimation of the proliferative activity of human breast cancer tissue by means of the Ki-67 and MIB-1 antibodies: Comparative studies on frozen and paraffin sections. Virchows Arch. 1995; 426: 435-439.
23. Jensen V, Ladekarl M, Holm-Nielsen P, Melsen F, Scerensen FB. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J. Pathol. 1995; 176: 343-352.
24. Japanese Breast Cancer Society. The general rules for clinical and pathological recording of breast cancer. Jpn. J. Surg. 1989; 19: 612-632.
25. Spiessl B, ed. International Union Against Cancer. TNM-Atlas: Illustrated Guide to the TNM/pTNM-classification of Malignant Tumours, 3rd edn. Springer-Verlag, Berlin, 1989.
26. Bravo R, Frank R, Blundell PA, MacDonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-8. Nature 1987; 326: 515-517.
27. Prelich G, Tan CK, Kostura M et al. Functional identity of proliferating cell nuclear antigen and a DNA polymerase-5 auxiliary protein. Nature 1987; 326: 517-520.
28. Sasaki K, Matsumura K, Tsuji T, Shinozaki F, Takahashi M. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer 1988; 62: 989-993.
29. Onda K, Davis RL, Shibuya M, Wilson CB, Hoshino T. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 1994; 74: 1921-1926.
30. Sasaki K, Murakami T, Kawasaki M, Takahashi M. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J. Cell. Physiol. 1987; 133: 579-584.
31. World Health Organization. Histological Typing of Breast Tumours. International Histological Classification of Tumours No. 2, 2nd edn. World Health Organization, Geneva, 1981.
32. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
33. Porter PL, Gown AM, Kramps SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors. Am. J. Pathol. 1992; 140: 145-153.
34. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl Cancer Inst. 1992; 84: 1109-1114.
35. Berger MS, Locher GW, Saurer S et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988; 48: 1238-1243.
36. Van de Vijver MJ, Peterse JL, Mooi WJ et al. Neu protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med. 1988; 319: 1239-1245.
37. Walker RA, Gullick WJ, Varley JM. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br. J. Cancer 1989; 60: 426-429.
38. Wright C, Angus B, Nicholson S et al. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res. 1989; 49: 2087-2090.
39. McGuire WL. Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. J. Clin. Oncol. 1988; 6: 1071-1072.
40. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary node negative breast cancer. N. Engl. J. Med. 1992; 326: 1756-1761.